Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial

Trial Profile

Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Bimatoprost (Primary)
  • Indications Graves ophthalmopathy
  • Focus Therapeutic Use
  • Acronyms BIMA
  • Most Recent Events

    • 29 Feb 2016 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials record.
    • 10 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 04 Mar 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top